Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 2429

1.

Comparative Persistence of the TNF Antagonists in Rheumatoid Arthritis - A Population-Based Cohort Study.

Fisher A, Bassett K, Wright JM, Brookhart MA, Freeman H, Dormuth CR.

PLoS One. 2014 Aug 20;9(8):e105193. doi: 10.1371/journal.pone.0105193. eCollection 2014.

PMID:
25141123
[PubMed - in process]
Free Article
2.

[Cost-minimization analysis of subcutaneous abatacept in the treatment of rheumatoid arthritis in Spain].

Ariza R, Van Walsem A, Canal C, Roldán C, Betegón L, Oyagüez I, Janssen K.

Farm Hosp. 2014 Jul 1;38(4):257-65. doi: 10.7399/fh.2014.38.4.1137. Spanish.

PMID:
25137158
[PubMed - in process]
3.

When to Adjust Therapy in Patients with Rheumatoid Arthritis After Initiation of Etanercept plus Methotrexate or Methotrexate Alone: Findings from a Randomized Study (COMET).

Dougados MR, van der Heijde DM, Brault Y, Koenig AS, Logeart IS.

J Rheumatol. 2014 Aug 15. pii: jrheum.131238. [Epub ahead of print]

PMID:
25128520
[PubMed - as supplied by publisher]
4.

Persistence and Dose Escalation of Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis.

Cannon GW, DuVall SL, Haroldsen CL, Caplan L, Curtis JR, Michaud K, Mikuls TR, Reimold A, Collier DH, Harrison DJ, Joseph GJ, Sauer BC.

J Rheumatol. 2014 Aug 15. pii: jrheum.140164. [Epub ahead of print]

PMID:
25128516
[PubMed - as supplied by publisher]
Free Article
5.

Treating to target with etanercept in rheumatoid arthritis: cost-effectiveness of dose reductions when remission is achieved.

Kobelt G.

Value Health. 2014 Jul;17(5):537-44. doi: 10.1016/j.jval.2014.04.005. Epub 2014 May 23.

PMID:
25128046
[PubMed - in process]
6.

Apoptosis and the FLIP and NF-kappa B proteins as pharmacodynamic criteria for biosimilar TNF-alpha antagonists.

Urbano PC, Soccol VT, Azevedo VF.

Biologics. 2014 Jul 31;8:211-20. doi: 10.2147/BTT.S57253. eCollection 2014. Review.

PMID:
25114503
[PubMed]
Free PMC Article
7.

Effects of Anti-TNF Alpha Drugs on Disability in Patients with Rheumatoid Arthritis: Long-Term Real-Life Data from the Lorhen Registry.

Filippini M, Bazzani C, Atzeni F, Sarzi Puttini P, Marchesoni A, Favalli EG, Caporali R, Cavagna L, Gorla R.

Biomed Res Int. 2014;2014:416892. doi: 10.1155/2014/416892. Epub 2014 Jul 6.

PMID:
25110678
[PubMed - in process]
Free PMC Article
8.

Drug Retention Rates and Treatment Discontinuation among Anti-TNF-α Agents in Psoriatic Arthritis and Ankylosing Spondylitis in Clinical Practice.

Fabbroni M, Cantarini L, Caso F, Costa L, Pagano VA, Frediani B, Manganelli S, Galeazzi M.

Mediators Inflamm. 2014;2014:862969. doi: 10.1155/2014/862969. Epub 2014 Jul 8.

PMID:
25110401
[PubMed - in process]
Free PMC Article
9.

Effects of Centrally Administered Etanercept on Behaviour, Microglia and Astrocytes in Mice Following a Peripheral Immune Challenge.

Lou Camara M, Corrigan F, Jaehne EJ, Jawahar MC, Anscomb H, Baune BT.

Neuropsychopharmacology. 2014 Aug 8. doi: 10.1038/npp.2014.199. [Epub ahead of print]

PMID:
25103178
[PubMed - as supplied by publisher]
10.

Etanercept-induced cystic acne.

Kashat M, Caretti K, Kado J.

Cutis. 2014 Jul;94(1):31-2.

PMID:
25101341
[PubMed - in process]
11.

Lung sarcoidosis in etanercept treated rheumatoid arthritis patient: a case report and review of the literature.

Thongpooswan S, Abrudescu A.

Case Rep Rheumatol. 2014;2014:358567. doi: 10.1155/2014/358567. Epub 2014 Jul 3.

PMID:
25097790
[PubMed]
Free PMC Article
12.

Myelitis and optic neuritis induced by a long course of etanercept in a patient with rheumatoid arthritis.

Yokoyama W, Takada K, Miyasaka N, Kohsaka H.

BMJ Case Rep. 2014 Aug 1;2014. pii: bcr2014205779. doi: 10.1136/bcr-2014-205779.

PMID:
25085953
[PubMed - in process]
13.

The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions.

Adelzadeh L, Jourabchi N, Wu JJ.

J Eur Acad Dermatol Venereol. 2014 Jul;28(7):846-52. doi: 10.1111/jdv.12307. Epub 2013 Nov 4.

PMID:
25081573
[PubMed - in process]
14.

RITUXIMAB AND TOCILIZUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS.

González-Vacarezza N, Alemán A, González G, Pérez A.

Int J Technol Assess Health Care. 2014 Jul 28:1-7. [Epub ahead of print]

PMID:
25068763
[PubMed - as supplied by publisher]
15.

Cost of Biologics per Treated Patient across Immune-Mediated Inflammatory Disease Indications in a Pharmacy Benefit Management Setting: A Retrospective Cohort Study.

Wu N, Lee YC, Shah N, Harrison DJ.

Clin Ther. 2014 Jul 22. pii: S0149-2918(14)00377-4. doi: 10.1016/j.clinthera.2014.06.014. [Epub ahead of print]

PMID:
25062652
[PubMed - as supplied by publisher]
16.

Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study.

Fleischmann R, Goldman JA, Leirisalo-Repo M, Zanetakis E, El-Kadi H, Kellner H, Bolce R, DeHoratius R, Wang J, Decktor D.

Curr Med Res Opin. 2014 Jul 30:1-11. [Epub ahead of print]

PMID:
25050591
[PubMed - as supplied by publisher]
17.

Effect of Etanercept, Infliximab and Methotrexate in the Treatment of Arthritis.

Wang L, Liu Y, Su X, Liu S.

Drug Res (Stuttg). 2014 Jul 22. [Epub ahead of print]

PMID:
25050521
[PubMed - as supplied by publisher]
18.

Rapidly Fatal Internal Carotid Artery Mycotic Aneurysm Rupture in a Rheumatoid Patient Taking a TNF-α Inhibitor: Case Report and Literature Review.

Bowers CA, Saad D, Clegg DO, Ng P, Clayton F, Haydoura S, Schmidt RH.

J Neurol Surg A Cent Eur Neurosurg. 2014 Jul 21. [Epub ahead of print]

PMID:
25045858
[PubMed - as supplied by publisher]
19.

Pigmented villonodular synovitis developing in a patient with rheumatoid arthritis.

Zhao X, Ji W, Qian X, Lu Y.

J Clin Rheumatol. 2014 Aug;20(5):283-6. doi: 10.1097/RHU.0000000000000119.

PMID:
25036563
[PubMed - in process]
20.

Etanercept: A Review of Its Use in Autoimmune Inflammatory Diseases.

Scott LJ.

Drugs. 2014 Jul 18. [Epub ahead of print]

PMID:
25034360
[PubMed - as supplied by publisher]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk